Sign Out
Hypersensitivity to any component of the preparation.
IMIGRAN should not be given to patients who have had a myocardial infarction or have ischaemic heart disease (IHD), Prinzmetal's angina/coronary vasospasm, peripheral vascular disease or patients who have symptoms or signs consistent with IHD.
IMIGRAN should not be administered to patients with a history of previous cerebrovascular accident (CVA) or transient ischaemic attack (TIA).
The use of IMIGRAN in patients with uncontrolled hypertension is contraindicated.
IMIGRAN should not be administered to patients with severe hepatic impairment.
The concomitant use of ergotamine or derivatives of ergotamine (including methysergide) is contraindicated (see Interactions).
Concurrent administration of monoamine oxidase inhibitors (MAOIs) and IMIGRAN is contraindicated. IMIGRAN must not be used within 2 weeks of discontinuation of therapy with MAOIs.
